FDA outlines 2027 AI guidance plans, expanding regulatory framework

The FDA announced plans to issue new AI-related guidances in 2027, building on its existing framework for AI-enabled medical devices. The move signals continued regulatory evolution but lacks specifics on scope or timing. This matters for medtech companies and investors navigating AI product approvals.